MK-6240
Phase 2- Indications
- Alzheimer's disease
Company intelligence / Profile preview
Cerveau Technologies
Boston, Massachusetts, USAcerveautechnologies.com ↗
- Ownership
- Public · LNTH
- Development stage
- Phase 2
01
Overview
MK‑6240, an F18-labeled PET imaging agent targeting tau tangles, has been used in over 60 academic and industry clinical trials worldwide to support diagnosis and staging of Alzheimer’s disease. It remains investigational and has not received regulatory approval for commercial use. The compound enables visualization of tau pathology progression following Braak stages in AD patients.
- Therapeutic areas
- Neurology
- Modalities
- Diagnostic radiopharmaceuticalsSmall molecule
- Industry
- Medical Imaging
02
Drug pipeline
1 asset03
Partnerships
Enigma Biomedical GroupSinotau Pharmaceutical GroupOver sixteen pharmaceutical companies using MK‑6240 as a biomarker tool in late-stage AD therapeutic developmentNumerous academic collaborations globally
Beyond the preview
Go deeper on Cerveau Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cerveau Technologies.